NasdaqGS:CABABiotechs
Cabaletta Bio (CABA) Is Up 34.2% After Early RESET-PV Data And US$150M Equity Raise
In early May 2026, Cabaletta Bio reported early RESET-PV trial data showing biologic and clinical activity for its rese-cel CAR T therapy in refractory pemphigus vulgaris patients treated at the lowest dose without chemotherapy preconditioning, alongside a completed US$150.00 million follow-on equity offering priced at US$2.90 per share.
An interesting angle for investors is Cabaletta’s 10-year commercial supply agreement with Cellares, which aims to support automated, higher-throughput...